论文部分内容阅读
目的了解瑞舒伐他汀片联合依折麦布片治疗高脂血症的降脂疗效和药物安全性。方法采用随机表法将120例患者分为A、B、C三组,A组每晚口服瑞舒伐他汀片和依折麦布片各10mg,B组每晚口服瑞舒伐他汀片20mg,C组每晚口服瑞舒伐他汀片10mg,临床观察16周,分别于治疗前、治疗16周时记录血脂各项指标及与药物有关的不良反应。结果三组患者在治疗前、16周时,分别记录血清总胆固醇(TC)、低密度脂蛋白(LDLC)、三酰甘油(TG)及高密度脂蛋白(HDL-C)的指标变化,A组的降脂幅度明显高于B组、C组,有统计学意义(P﹤0.05),药物不良反应无明显差异。结论本组研究结果证实瑞舒伐他汀片联合依折麦布片的降脂效果明显优于单纯应用瑞舒伐他汀片,药物安全性无明显差异。
Objective To understand the lipid-lowering efficacy and drug safety of rosuvastatin tablet combined with ezetimibe in the treatment of hyperlipidemia. Methods One hundred and twenty patients were randomly divided into A, B and C groups. Group A received 10 mg of rosuvastatin tablets and ezetimibe per night, while group B received 20 mg of rosuvastatin tablets per night. C group oral administration of rosuvastatin tablets 10mg per night, clinical observation of 16 weeks, respectively, before treatment and 16 weeks of treatment when recording the indicators of lipid and drug-related adverse reactions. Results The changes of serum total cholesterol (TC), low density lipoprotein (LDLC), triglyceride (TG) and high density lipoprotein (HDL-C) were recorded in three groups before treatment and at 16 weeks The rate of lipid-lowering in the group was significantly higher than that in group B and group C (P <0.05), and there was no significant difference in adverse drug reactions. Conclusion The results of this study confirmed that rosuvastatin tablets combined with ezetimibe tablets lipid-lowering effect was significantly better than the simple application of rosuvastatin tablets, drug safety no significant difference.